brl 42810 has been researched along with Chronic Hepatitis B in 60 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with chronic hepatitis B infection and detectable HBV DNA received lamivudine and famciclovir combination therapy." | 9.11 | Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection. ( Alsatie, M; Chalasani, N; Eckert, G; Kwo, PY; Lumeng, L; Shen, H, 2004) |
| "Hepatitis B e antigen-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B (CHBe-) exhibits a high relapse rate on monotherapy with lamivudine or interferon-alpha (IFN-alpha)." | 9.11 | Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a. ( Berr, F; Etzrodt, G; Klecker, C; Liebert, UG; Maier, M; Oesen, U; Schiefke, I; Tannapfel, A, 2004) |
| "We examined whether combination therapy with thymosin-alpha1 and famciclovir would induce hepatitis B e antigen seroconversion in patients with chronic hepatitis B infection in the immune-tolerant phase without inducing significant hepatic necro-inflammation." | 9.10 | Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. ( Au, WS; Fong, DY; Hou, J; Kung, HF; Lam, SK; Lau, GK; Lin, M; Nanji, A; Yuen, ST, 2002) |
| "Lamivudine (LMV) is the only nucleoside analogue approved for the treatment of chronic hepatitis B (CHB)." | 7.72 | Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure. ( Ayres, A; Bartholomeusz, A; Lam, KC; Lau, G; Lee, JY; Locarnini, S, 2003) |
| "To evaluate the clinical efficacy of combined treatment with lamivudine and famciclovir on chronic hepatitis B virus (HBV) infection." | 7.72 | [Treatment of patients with chronic hepatitis B virus infect ion with lamivudine combined with famciclovir]. ( Ji, W; Li, L; Su, HB; Wang, HF, 2003) |
| "We have analyzed the molecular dynamics of emergence of drug-resistant strains in patients receiving lamivudine therapy for chronic hepatitis B." | 7.70 | Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. ( Abidi, H; Ahmed, S; Berby, F; Johnson, M; Merle, P; Nafa, S; Pichoud, C; Stuyver, L; Tavan, D; Trépo, C; Zoulim, F, 2000) |
| "Classic patients with chronic hepatitis B are positive for hepatitis Be-antigen (HBeAg) and HBV-DNA." | 6.42 | Thymosin in the treatment of HBeAg-negative chronic hepatitis B. ( Ozden, N; Saruc, M; Yuceyar, H, 2003) |
| "Patients with chronic hepatitis B infection and detectable HBV DNA received lamivudine and famciclovir combination therapy." | 5.11 | Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection. ( Alsatie, M; Chalasani, N; Eckert, G; Kwo, PY; Lumeng, L; Shen, H, 2004) |
| "Hepatitis B e antigen-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B (CHBe-) exhibits a high relapse rate on monotherapy with lamivudine or interferon-alpha (IFN-alpha)." | 5.11 | Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a. ( Berr, F; Etzrodt, G; Klecker, C; Liebert, UG; Maier, M; Oesen, U; Schiefke, I; Tannapfel, A, 2004) |
| "Twelve patients with a history of childhood malignancy and chronic hepatitis B were treated with prednisone for 4 weeks (0." | 5.10 | Serological and molecular response on combined antiviral treatment in children with chronic hepatitis B after pediatric malignancy. ( Benesch, M; Deutsch, J; Dornbusch, HJ; Kerbl, R; Kessler, HH; Lackner, H; Moser, A; Schwinger, W; Sovinz, P; Urban, C, 2002) |
| "We examined whether combination therapy with thymosin-alpha1 and famciclovir would induce hepatitis B e antigen seroconversion in patients with chronic hepatitis B infection in the immune-tolerant phase without inducing significant hepatic necro-inflammation." | 5.10 | Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. ( Au, WS; Fong, DY; Hou, J; Kung, HF; Lam, SK; Lau, GK; Lin, M; Nanji, A; Yuen, ST, 2002) |
| "There are two licensed drugs for chronic hepatitis B virus (HBV), interferon alfa and lamivudine, with similar efficacy rates." | 4.81 | How will we use the new antiviral agents for hepatitis B? ( Perrillo, RP, 2002) |
| "After several nucleoside analogues have been tested against chronic hepatitis B virus (HBV) infection with minimal success, lamivudine seems to be a highly effective new therapeutic option." | 4.79 | Experience with lamivudine against hepatitis B virus. ( Jaeckel, E; Manns, MP, 1997) |
| "Lamivudine (LMV) is the only nucleoside analogue approved for the treatment of chronic hepatitis B (CHB)." | 3.72 | Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure. ( Ayres, A; Bartholomeusz, A; Lam, KC; Lau, G; Lee, JY; Locarnini, S, 2003) |
| "To evaluate the clinical efficacy of combined treatment with lamivudine and famciclovir on chronic hepatitis B virus (HBV) infection." | 3.72 | [Treatment of patients with chronic hepatitis B virus infect ion with lamivudine combined with famciclovir]. ( Ji, W; Li, L; Su, HB; Wang, HF, 2003) |
| "Therapy of chronic hepatitis B virus (HBV) infection with the polymerase inhibitor lamivudine frequently is associated with the emergence of viral resistance." | 3.72 | The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. ( Arnold, E; Das, K; Delaney, WE; Gibbs, CS; Miller, MD; Westland, CE; Xiong, S; Yang, H, 2003) |
| "Treatment for chronic hepatitis B with lamivudine is often hampered by the emergence of point mutations in the YMDD motif of the HBV DNA polymerase gene that confer drug resistance." | 3.72 | Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain. ( Echevarría, JM; León, P; Pozo, F, 2004) |
| "Nucleoside analogues such as lamivudine for chronic hepatitis B have an excellent safety profile while patients are on therapy but reactivation flares occur in 19-50% of patients after stopping therapy, some of whom develop liver decompensation." | 3.71 | Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. ( Guan, R; Kajiji, T; Lim, SG; Rajnakova, A; Wai, CT, 2002) |
| "We have analyzed the molecular dynamics of emergence of drug-resistant strains in patients receiving lamivudine therapy for chronic hepatitis B." | 3.70 | Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. ( Abidi, H; Ahmed, S; Berby, F; Johnson, M; Merle, P; Nafa, S; Pichoud, C; Stuyver, L; Tavan, D; Trépo, C; Zoulim, F, 2000) |
| "Classic patients with chronic hepatitis B are positive for hepatitis Be-antigen (HBeAg) and HBV-DNA." | 2.42 | Thymosin in the treatment of HBeAg-negative chronic hepatitis B. ( Ozden, N; Saruc, M; Yuceyar, H, 2003) |
| "Lamivudine has been demonstrated to have consistent efficacy and safety in large-scale, phase III clinical trials." | 2.41 | Nucleoside analogues in the treatment of chronic hepatitis B. ( Leung, N, 2000) |
| "Due to its low efficacy, 40% in the treatment of chronic hepatitis B and 10-20% in the treatment of chronic hepatitis C, and to its adverse events, in some cases severe, new antiviric molecules are being investigated." | 2.40 | [New antiviral agents in the treatment of chronic hepatitis B and C]. ( Córdoba Cortijo, J; López Viedma, B; Olaso Peiró, V, 1998) |
| "Only one hepatocellular carcinoma developed, which was successfully treated by locoregional ablative therapy." | 1.33 | Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. ( Bara, C; Böker, KH; Deterding, K; Haverich, A; Manns, MP; Meyer, S; Pethig, K; Potthoff, A; Tillmann, HL; Wedemeyer, H, 2006) |
| "Lamivudine was effective also after famciclovir breakthrough in 94% of patients." | 1.31 | [Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases]. ( Bechstein, WO; Berg, T; Hopf, U; Langrehr, JM; Müller, AR; Naumann, U; Neuhaus, P; Neuhaus, R; Platz, KP; Rayes, N; Seehofer, D; Steinmüller, T, 2000) |
| "Lamivudine 3 mg/kg was administered on a compassionate-use basis for 14-36 months." | 1.31 | Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children. ( Bar-Nathan, N; Ben-Ari, Z; Dinari, G; Mor, E; Shapira, R; Sokal, EM; Tur-Kaspa, R, 2001) |
| "Medical therapy of chronic hepatitis B aims at halting progression towards cirrhosis/hepatocellular carcinoma by inhibiting replication of hepatitis B virus in a sustained fashion (viral elimination)." | 1.30 | [Drug therapy of chronic hepatitis B]. ( Lavanchy, D; Renner, EL, 1998) |
| "Prolonged therapy for chronic hepatitis B (HBV) with nucleoside analogs may result in the emergence of HBV mutants resistant to antivirals." | 1.30 | Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. ( Pichoud, C; Seignères, B; Trépo, C; Wang, Z; Zoulim, F, 1999) |
| "A consensus meeting on the treatment of chronic hepatitis B infection was conducted in Hong Kong, in August 1997." | 1.30 | Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective. ( Carman, WF; Lam, SK; Lau, GK; Locarnini, SA; Lu, ZM; Okuda, K; Williams, R, 1999) |
| "We described two chronic hepatitis B carriers (both hepatitis B e antigen negative), who cleared HBsAg after allogeneic bone marrow transplantation." | 1.30 | Histological changes during clearance of chronic hepatitis B virus infection by adoptive immunity transfer. ( Au, WY; Lau, GK; Liang, R; Wu, PC; Yuen, ST, 1999) |
| "Lamivudine was well tolerated and liver function improved." | 1.30 | Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine. ( Bechstein, WO; Budde, K; Hocher, B; Krüger, DH; Meisel, H; Neuhaus, P; Neumayer, HH; Preikschat, P; Reinke, P, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (30.00) | 18.2507 |
| 2000's | 42 (70.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Menne, S | 1 |
| Asif, G | 1 |
| Narayanasamy, J | 1 |
| Butler, SD | 1 |
| George, AL | 1 |
| Hurwitz, SJ | 1 |
| Schinazi, RF | 1 |
| Chu, CK | 1 |
| Cote, PJ | 1 |
| Gerin, JL | 3 |
| Tennant, BC | 3 |
| Lai, CL | 1 |
| Yuen, MF | 1 |
| Hui, CK | 1 |
| Garrido-Lestache, S | 1 |
| Cheng, CT | 1 |
| Lai, YP | 1 |
| Demirtürk, N | 1 |
| Usluer, G | 1 |
| Ozgünes, I | 1 |
| Colak, H | 1 |
| Kartal, ED | 1 |
| Dinçer, S | 1 |
| Papatheodoridis, GV | 1 |
| Dimou, E | 1 |
| Papadimitropoulos, V | 1 |
| Lim, SG | 1 |
| Wai, CT | 1 |
| Rajnakova, A | 1 |
| Kajiji, T | 1 |
| Guan, R | 1 |
| Wolters, LM | 3 |
| Hansen, BE | 1 |
| Niesters, HG | 3 |
| de Man, RA | 4 |
| Lackner, H | 1 |
| Moser, A | 1 |
| Benesch, M | 1 |
| Deutsch, J | 1 |
| Kessler, HH | 1 |
| Kerbl, R | 1 |
| Schwinger, W | 1 |
| Dornbusch, HJ | 1 |
| Sovinz, P | 1 |
| Urban, C | 1 |
| Li, L | 2 |
| Shao, Q | 1 |
| Zhang, J | 1 |
| Ji, D | 1 |
| Ayres, A | 1 |
| Bartholomeusz, A | 1 |
| Lau, G | 1 |
| Lam, KC | 1 |
| Lee, JY | 1 |
| Locarnini, S | 3 |
| Wang, HF | 1 |
| Su, HB | 1 |
| Ji, W | 1 |
| Saruc, M | 1 |
| Ozden, N | 1 |
| Yuceyar, H | 1 |
| Lagget, M | 1 |
| Rizzetto, M | 1 |
| Delaney, WE | 1 |
| Yang, H | 1 |
| Westland, CE | 1 |
| Das, K | 1 |
| Arnold, E | 1 |
| Gibbs, CS | 2 |
| Miller, MD | 1 |
| Xiong, S | 1 |
| León, P | 1 |
| Pozo, F | 1 |
| Echevarría, JM | 1 |
| Shen, H | 1 |
| Alsatie, M | 1 |
| Eckert, G | 1 |
| Chalasani, N | 1 |
| Lumeng, L | 1 |
| Kwo, PY | 1 |
| Schiefke, I | 1 |
| Klecker, C | 1 |
| Maier, M | 1 |
| Oesen, U | 1 |
| Etzrodt, G | 1 |
| Tannapfel, A | 1 |
| Liebert, UG | 1 |
| Berr, F | 1 |
| Sagir, A | 1 |
| Avci, A | 1 |
| Erhardt, A | 1 |
| Lörke, J | 1 |
| Heintges, T | 1 |
| Häussinger, D | 1 |
| Wang, ZY | 1 |
| Guo, SH | 1 |
| Zhang, DF | 1 |
| Zhao, YR | 1 |
| Ren, H | 1 |
| Zhou, XQ | 1 |
| Xu, DZ | 1 |
| Sun, JY | 1 |
| Yao, JL | 1 |
| Lu, WL | 1 |
| Potthoff, A | 1 |
| Tillmann, HL | 3 |
| Bara, C | 1 |
| Deterding, K | 1 |
| Pethig, K | 2 |
| Meyer, S | 1 |
| Haverich, A | 2 |
| Böker, KH | 3 |
| Manns, MP | 4 |
| Wedemeyer, H | 2 |
| Krüger, M | 1 |
| Trautwein, C | 1 |
| Bode, U | 1 |
| Oldhafer, K | 1 |
| Maschek, H | 1 |
| Broelsch, CE | 1 |
| Pichlmayr, R | 1 |
| McCaughan, G | 1 |
| Angus, P | 1 |
| Bowden, S | 1 |
| Shaw, T | 2 |
| Breschkin, A | 1 |
| Sheil, R | 1 |
| Tassopoulos, NC | 1 |
| Olaso Peiró, V | 1 |
| López Viedma, B | 1 |
| Córdoba Cortijo, J | 1 |
| Honkoop, P | 1 |
| Jaeckel, E | 1 |
| Marques, AR | 1 |
| Lau, DT | 1 |
| McKenzie, R | 1 |
| Straus, SE | 1 |
| Hoofnagle, JH | 1 |
| Renner, EL | 1 |
| Lavanchy, D | 1 |
| Pichoud, C | 4 |
| Seignères, B | 2 |
| Wang, Z | 1 |
| Trépo, C | 6 |
| Zoulim, F | 5 |
| Main, J | 1 |
| McCarron, B | 1 |
| Thomas, HC | 1 |
| Lau, GK | 5 |
| Carman, WF | 2 |
| Locarnini, SA | 1 |
| Okuda, K | 1 |
| Lu, ZM | 1 |
| Williams, R | 1 |
| Lam, SK | 2 |
| Yuen, ST | 2 |
| Au, WY | 1 |
| Wu, PC | 1 |
| Liang, R | 1 |
| Meisel, H | 1 |
| Preikschat, P | 1 |
| Reinke, P | 1 |
| Hocher, B | 1 |
| Budde, K | 1 |
| Bechstein, WO | 3 |
| Neuhaus, P | 3 |
| Krüger, DH | 1 |
| Neumayer, HH | 1 |
| Young, CL | 1 |
| Hultgren, C | 1 |
| Weiland, O | 1 |
| Milich, DR | 1 |
| Sällberg, M | 1 |
| Petzold, DR | 1 |
| Flemming, P | 1 |
| Vollmar, J | 1 |
| Bastürk, M | 1 |
| Goldmann, E | 1 |
| Griffin, KE | 1 |
| Berby, F | 2 |
| Stuyver, L | 2 |
| Petit, MA | 1 |
| Ahmed, SS | 1 |
| Hantz, O | 1 |
| Freiman, JS | 1 |
| McCaughan, GW | 1 |
| Korba, BE | 2 |
| Cote, P | 2 |
| Hornbuckle, W | 2 |
| Schinazi, R | 1 |
| Zavaglia, C | 1 |
| Airoldi, A | 1 |
| Pinzello, G | 1 |
| Hou, J | 3 |
| Fen, X | 1 |
| Nie, Z | 1 |
| Jezek, P | 1 |
| Atkinson, G | 1 |
| Boon, R | 1 |
| Young, C | 2 |
| Tsiang, M | 1 |
| Yuen, S | 1 |
| Zhang, L | 1 |
| Lam, S | 1 |
| Marcellin, P | 1 |
| Habal, F | 1 |
| Desmond, P | 1 |
| Wright, T | 1 |
| Rose, T | 1 |
| Jurewicz, R | 1 |
| Leung, N | 1 |
| Nafa, S | 1 |
| Ahmed, S | 1 |
| Tavan, D | 1 |
| Johnson, M | 1 |
| Merle, P | 1 |
| Abidi, H | 1 |
| Seehofer, D | 2 |
| Rayes, N | 2 |
| Naumann, U | 1 |
| Neuhaus, R | 2 |
| Berg, T | 2 |
| Hopf, U | 1 |
| Langrehr, JM | 1 |
| Steinmüller, T | 1 |
| Platz, KP | 1 |
| Müller, AR | 2 |
| Suárez García, E | 1 |
| Romero Gómez, M | 1 |
| Grande Santamaría, L | 1 |
| Forns, X | 1 |
| Sánchez-Tapias, JM | 1 |
| Fried, MW | 1 |
| Sommadossi, JP | 1 |
| Shapira, R | 1 |
| Mor, E | 1 |
| Bar-Nathan, N | 1 |
| Sokal, EM | 1 |
| Tur-Kaspa, R | 1 |
| Dinari, G | 1 |
| Ben-Ari, Z | 1 |
| Perrillo, RP | 1 |
| Di Bisceglie, AM | 1 |
| Nanji, A | 1 |
| Fong, DY | 1 |
| Au, WS | 1 |
| Lin, M | 1 |
| Kung, HF | 1 |
17 reviews available for brl 42810 and Chronic Hepatitis B
| Article | Year |
|---|---|
Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
Topics: 2-Aminopurine; Antiviral Agents; Cross Reactions; Drug Resistance, Viral; Famciclovir; Hepatitis B v | 2002 |
Thymosin in the treatment of HBeAg-negative chronic hepatitis B.
Topics: 2-Aminopurine; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Hepatitis B e Antigens; Hep | 2003 |
Current pharmacotherapy for the treatment of chronic hepatitis B.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Clinical Trials as Topic; Famciclovir; Hepatitis B e Antig | 2003 |
[New approaches in the treatment of hepatitis B].
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Contrai | 2004 |
Chronic hepatitis B: interferon-monotherapy or combination with nucleoside analogues?
Topics: 2-Aminopurine; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Hepatitis B, Chronic; Human | 1998 |
[New antiviral agents in the treatment of chronic hepatitis B and C].
Topics: 2-Aminopurine; Antimetabolites; Antiviral Agents; Clinical Trials as Topic; Famciclovir; Hepatitis B | 1998 |
Experience with lamivudine against hepatitis B virus.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; F | 1997 |
Treatment of chronic viral hepatitis.
Topics: 2-Aminopurine; Animals; Antimetabolites; Antiviral Agents; Carcinoma, Hepatocellular; Disease Models | 1998 |
New antiviral agents for the therapy of chronic hepatitis B virus infection.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Microbial; Dr | 1999 |
Famciclovir update. Chronic hepatitis B.
Topics: 2-Aminopurine; Antiviral Agents; Clinical Trials, Phase II as Topic; Famciclovir; Hepatitis B, Chron | 1999 |
Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; DNA, Viral; Famciclovir; Hepatitis B e Antigens; Hepatitis | 2000 |
Antiviral therapy of HBV- and HCV-induced liver cirrhosis.
Topics: 2-Aminopurine; Antiviral Agents; Clinical Trials as Topic; Famciclovir; Female; Hepatitis B, Chronic | 2000 |
Nucleoside analogues in the treatment of chronic hepatitis B.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Deoxycytidine; Emtricitabine; Famciclovir; Hepatitis B e A | 2000 |
Nucleoside analogues and other investigational modalities for the treatment of chronic hepatitis B.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Arabinofuranosyluracil; Clinical Trials as Topic; Combined | 1996 |
Hepatitis B infection in China.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; China; Deoxycytidine; DNA, Viral; Drug Therapy, Combinatio | 2001 |
Nucleoside analogues for chronic hepatitis B.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Famciclovir; Ganciclovir; Guanine; Hepatitis B virus; Hepa | 2001 |
How will we use the new antiviral agents for hepatitis B?
Topics: 2-Aminopurine; Adenine; Alanine Transaminase; Antiviral Agents; Drug Resistance; Drug Therapy, Combi | 2002 |
16 trials available for brl 42810 and Chronic Hepatitis B
| Article | Year |
|---|---|
Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy.
Topics: 2-Aminopurine; Adolescent; Adult; Antiviral Agents; China; DNA, Viral; Famciclovir; Female; Hepatiti | 2002 |
Comparison of different treatment combinations for chronic hepatitis B infection.
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Administration Schedule; | 2002 |
Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir.
Topics: 2-Aminopurine; Adult; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Female; Ganciclovir; | 2002 |
Serological and molecular response on combined antiviral treatment in children with chronic hepatitis B after pediatric malignancy.
Topics: 2-Aminopurine; Adolescent; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Drug Therapy, Comb | 2002 |
[Famciclovir treatment of patients with chronic hepatitis B virus infection].
Topics: 2-Aminopurine; Adolescent; Aged; Antiviral Agents; Famciclovir; Female; Hepatitis B virus; Hepatitis | 2002 |
Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection.
Topics: 2-Aminopurine; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Adm | 2004 |
Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
Topics: 2-Aminopurine; Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents | 2004 |
[Clinical investigation of famciclovir in chronic hepatitis B patients irresponsive to alpha interferon treatment].
Topics: 2-Aminopurine; Adolescent; Adult; Antiviral Agents; Double-Blind Method; Famciclovir; Female; Follow | 2005 |
Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study.
Topics: 2-Aminopurine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Famciclovir; Female; | 1996 |
Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B.
Topics: 2-Aminopurine; Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; DNA, Vira | 1998 |
Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial.
Topics: 2-Aminopurine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combin | 1999 |
Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.
Topics: 2-Aminopurine; Adult; Amino Acid Sequence; Antiviral Agents; Cloning, Molecular; Drug Resistance, Mi | 2000 |
Famciclovir in chronic hepatitis B: results of a dose-finding study.
Topics: 2-Aminopurine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Dose-Response Relationship | 2000 |
Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.
Topics: 2-Aminopurine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Famciclov | 2000 |
A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B.
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Alanine Transaminase; DNA, Viral; Double-Blind Method; Famci | 2000 |
Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase.
Topics: 2-Aminopurine; Adjuvants, Immunologic; Adolescent; Adult; Antiviral Agents; Cell Division; Cells, Cu | 2002 |
27 other studies available for brl 42810 and Chronic Hepatitis B
| Article | Year |
|---|---|
Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.
Topics: Administration, Oral; Animals; Antiviral Agents; Dioxolanes; DNA, Viral; Dose-Response Relationship, | 2007 |
Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.
Topics: 2-Aminopurine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Bilirubin; DNA, Viral; Drug Resi | 2002 |
Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.
Topics: 2-Aminopurine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Famciclov | 2003 |
[Treatment of patients with chronic hepatitis B virus infect ion with lamivudine combined with famciclovir].
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Famciclo | 2003 |
The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
Topics: 2-Aminopurine; Amino Acid Sequence; Antiviral Agents; Drug Resistance, Viral; Famciclovir; Hepatitis | 2003 |
Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
Topics: 2-Aminopurine; Amino Acid Sequence; Antiviral Agents; Diagnostic Tests, Routine; DNA Mutational Anal | 2004 |
Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy.
Topics: 2-Aminopurine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Famciclovir; Female; Heart | 2006 |
Retransplantation for precore mutant-related chronic hepatitis B infection: prolonged survival in a patient receiving sequential ganciclovir/famciclovir therapy.
Topics: 2-Aminopurine; Antiviral Agents; DNA, Viral; Famciclovir; Follow-Up Studies; Ganciclovir; Graft Reje | 1996 |
Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene.
Topics: 2-Aminopurine; Alanine Transaminase; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Famc | 1998 |
[Drug therapy of chronic hepatitis B].
Topics: 2-Aminopurine; Antiviral Agents; Famciclovir; Hepatitis B virus; Hepatitis B, Chronic; Humans; Inter | 1998 |
Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.
Topics: 2-Aminopurine; Adult; Amino Acid Sequence; Antiviral Agents; Biomarkers; Cells, Cultured; Cloning, M | 1999 |
Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective.
Topics: 2-Aminopurine; Adjuvants, Immunologic; Animals; Antiviral Agents; Asia; Drug Therapy, Combination; F | 1999 |
Histological changes during clearance of chronic hepatitis B virus infection by adoptive immunity transfer.
Topics: 2-Aminopurine; Adolescent; Adult; Antiviral Agents; Bone Marrow Transplantation; Famciclovir; Hepati | 1999 |
Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine.
Topics: 2-Aminopurine; Antiviral Agents; DNA, Viral; Famciclovir; Follow-Up Studies; Genetic Variation; Hepa | 1999 |
Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection.
Topics: 2-Aminopurine; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Famciclovir; Hepatitis | 1999 |
Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B.
Topics: 2-Aminopurine; Antibodies, Viral; Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Tri | 2000 |
Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Carrier State; Disease Models, Animal; Drug Therapy, Combi | 2000 |
Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Famciclovir; Hepatitis B Virus, Woodchuck; Hepatitis B, Ch | 2000 |
[Dynamic changes of hepatitis B virus during treatment with lamivudine versus lamivudine plus famciclovir].
Topics: 2-Aminopurine; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Female; | 2000 |
Combination chemotherapy for hepatitis B virus: the final solution?
Topics: 2-Aminopurine; Antiviral Agents; DNA, Viral; Drug Resistance; Drug Therapy, Combination; Famciclovir | 2000 |
Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Aged, 80 and over; DNA, Viral; Drug Resistance, Microbial; D | 2000 |
[Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases].
Topics: 2-Aminopurine; Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedu | 2000 |
Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation.
Topics: 2-Aminopurine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Microbial; Drug | 2000 |
[Current treatment of hepatitis B].
Topics: 2-Aminopurine; Adenine; Anti-Inflammatory Agents; Antiviral Agents; DNA Replication; Famciclovir; Fo | 2001 |
[Laboratory diagnosis of hepatitis B].
Topics: 2-Aminopurine; Acute Disease; Antiviral Agents; DNA Replication; DNA, Viral; Drug Resistance; Famcic | 2001 |
Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children.
Topics: 2-Aminopurine; Adolescent; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; Cystic F | 2001 |
Combination therapy for hepatitis B.
Topics: 2-Aminopurine; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Forecasting; Hepatitis B, C | 2002 |